Breaking News

Statement by US Secretary of Labor Walsh on November Jobs Report B-21 Raider makes public debut; will become backbone of Air Force’s bomber fleet > Air Force > Article Display Africa-U.S.: Commercial Ties will Shape the Partnership in the 21st Century Readout of Secretary Raimondo’s Meeting with Mexican Secretary of Economy Raquel Buenrostro Readout of Secretary Raimondo’s Meeting with French Minister of the Economy, Finance, and Industrial and Digital Sovereignty Bruno Le Maire US Department of Labor finds Family Dollar Stores again exposing workers to fire, entrapment, struck-by hazards, this time at Richmond Hill location The 91st Annual California State Capitol Tree Lighting Ceremony Heightened Financing, Women and Youth Participation Vital for Peace Efforts, Speakers Tell Economic and Social Council, Peacebuilding Commission

Issued: London, UK

  • Mr Tom de Swaan will succeed Sir Crispin Davis as Chairman of the Remuneration Committee with effect from 1 January 2013. Mr de Swaan has been a member of the Remuneration Committee since May 2009.
  • Ms Judy Lewent will succeed Mr Tom de Swaan as Chair of the Audit & Risk Committee with effect from 1 January 2013.  Ms Lewent has been a member of the Audit & Risk Committee since April 2011.  Mr de Swaan will remain a member of the Audit & Risk Committee following Ms Lewent’s appointment. 
  • Sir Deryck Maughan will succeed Sir Robert Wilson as Senior Independent Non-Executive Director with effect from the closure of GSK’s AGM in 2013.

In addition, Mr James Murdoch has decided not to stand for re-election to the Board at GSK’s AGM in 2012.

Commenting on the changes, Sir Christopher Gent, Chairman of GSK, said: “These changes represent a proactive set of steps to ready the Board for future changes in its composition as a number of senior, long-standing Directors stand down in 2013.  I would like to put on record my thanks to Crispin, Robert and Larry who have served GSK’s Board with distinction for many years and I’m sure will continue to do so until their retirement next year.”

“In addition, James Murdoch has decided to stand down from the Board with effect from this year’s AGM.  James has taken this decision to focus on his current duties as Non-executive Chairman of BSkyB, and following his decision to re-locate to the United States, as Chairman and Chief Executive, International, of News Corporation. On behalf of the Board, I would like to thank James for the very strong contribution he has made since he was appointed in 2009 and wish him well for the future.”

Victoria Whyte
Company Secretary

Notes:

GSK Board of Directors:

Sir Christopher Gent

Non-Executive Chairman

Sir Andrew Witty

Chief Executive Officer

Simon Dingemans

Chief Financial Officer

Moncef Slaoui

Executive Director, Chairman, Research & Development

Professor Sir Roy Anderson

Independent Non-Executive Director

Dr Stephanie Burns

Independent Non-Executive Director

Ms Stacey Cartwright

Independent Non-Executive Director

Mr Lawrence Culp

Independent Non-Executive Director

Sir Crispin Davis

Independent Non-Executive Director

Ms Judy Lewent

Independent Non-Executive Director

Sir Deryck Maughan

Independent Non-Executive Director

Mr James Murdoch

Independent Non-Executive Director

Dr Daniel Podolsky

Independent Non-Executive Director

Mr Tom de Swaan

Independent Non-Executive Director

Sir Robert Wilson

Senior Independent Non-Executive Director

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

 

Stephen Rea

+44 (0) 20 8047 5502

(London)

 

Sarah Spencer

+44 (0) 20 8047 5502

(London)

 

David Daley

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Kevin Colgan

+1 919 483 2839

(North Carolina)

 

Melinda Stubbee

+1 919 483 2839

(North Carolina)

 

Sarah Alspach

+1 919 483 2839

(Washington, DC)

 

Jennifer Armstrong

+1 919 483 2839

(Philadelphia)

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

 

Tom Curry

+ 1 215 751 5419

(Philadelphia)

 

Gary Davies

+ 44 (0) 20 8047 5503

(London)

 

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

 

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

Source link